Trial reportJournal of the American Heart Association2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
Trial report in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Progress in the treatment of diabetic cardiomyopathy, a systematic review.Pharmacology research & perspectives · 2024Pooled it
- Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.BMC cardiovascular disorders · 2022Pooled it
- Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2YJournal of the American Heart Association · 2019Trial
- Association Between Ticagrelor and Glucose Homeostasis Regulation: Insights from Genetic and Transcriptomic Analyses.Biochemical genetics · 2026Article
- Risk of New-Onset Ischaemic and Haemorrhagic Stroke in Patients With Type 2 Diabetes With Chronic Kidney Disease on SGLT-2 Inhibitor Users: A Population-Based Cohort Study.Diabetes/metabolism research and reviews · 2026Article
- Prognostic impact of proteinuria in diabetic patients without chronic kidney disease undergoing percutaneous coronary intervention.Cardiovascular diabetology. Endocrinology reports · 2025Article
- What is the Optimal Antiplatelet Therapy in Type 2 Diabetes Mellitus Patients with Small Diameter Stents?Anatolian journal of cardiology · 2025Article
- Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents.Anatolian journal of cardiology · 2025Article
- Clopidogrel-Mediated P2YJACC. Basic to translational science · 2024Article
- Management Considerations for Acute Coronary Syndromes in Chronic Kidney Disease.Current cardiology reports · 2024Review
- Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Review
- Impact of Coexisting Risk Factors on Outcomes in Patients with Acute Coronary Syndrome: A Real-World Analysis Using the Taiwan Chang Gung Research Database.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Reversal of Platelet Inhibition in Patients Receiving Ticagrelor.Reviews in cardiovascular medicine · 2022Review
- Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status.International journal of environmental research and public health · 2022Review
- Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease.Journal of clinical medicine · 2022Review
- Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome.Journal of interventional cardiology · 2022Article
- Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines.Frontiers in pharmacology · 2022Review
- Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Observational
- Antithrombotic therapy in diabetes: which, when, and for how long?European heart journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.